Minerva Total Stockholder Equity vs Current Deferred Revenue Analysis

NERV Stock

USD 2.26 0.00 0.00%

Minerva Neurosciences financial indicator trend analysis is infinitely more than just investigating Minerva Neurosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Minerva Neurosciences is a good investment. Please check the relationship between Minerva Neurosciences Total Stockholder Equity and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.

Total Stockholder Equity vs Current Deferred Revenue

Total Stockholder Equity vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Minerva Neurosciences Total Stockholder Equity account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.

The correlation between Minerva Neurosciences' Total Stockholder Equity and Current Deferred Revenue is 0.33. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Minerva Neurosciences, assuming nothing else is changed. The correlation between historical values of Minerva Neurosciences' Total Stockholder Equity and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Minerva Neurosciences are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Stockholder Equity i.e., Minerva Neurosciences' Total Stockholder Equity and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Minerva Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Minerva Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Minerva Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Minerva Stock please use our How to Invest in Minerva Neurosciences guide.At this time, Minerva Neurosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is expected to grow at the current pace this year, whereas Enterprise Value Over EBITDA is likely to drop (3.93) in 2024.

	2023	2024 (projected)
Extraordinary Items	8.5M	7.5M
Reconciled Depreciation	29.6K	57.8K

Extraordinary Items Reconciled Depreciation

Minerva Neurosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Good Will	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Term Debt
Total Assets		-0.47	0.81	0.76	-0.55	-0.34	0.65	0.96	0.65	0.46	0.04	0.62	0.48	0.96	0.7	0.04	0.18	0.72	0.63	0.63	0.02	0.75	0.69	0.36	0.17	0.36
Other Current Liab	-0.47		-0.48	-0.4	0.0	0.11	0.06	-0.5	-0.27	-0.24	-0.68	-0.28	-0.24	-0.5	-0.44	0.25	-0.7	-0.24	-0.45	-0.28	0.16	-0.28	-0.2	-0.18	-0.71	0.1
Total Current Liabilities	0.81	-0.48		0.66	-0.6	-0.26	0.63	0.73	0.55	0.34	0.32	0.49	0.31	0.73	0.65	-0.05	0.37	0.67	0.65	0.59	0.05	0.71	0.65	0.16	0.39	0.01
Total Stockholder Equity	0.76	-0.4	0.66		-0.38	0.26	0.31	0.67	0.2	-0.04	-0.02	0.14	-0.1	0.66	0.7	-0.58	0.14	0.33	0.19	0.88	-0.49	0.88	0.24	-0.23	0.15	0.33
Net Debt	-0.55	0.0	-0.6	-0.38		0.29	-0.75	-0.56	-0.45	-0.37	0.0	-0.42	-0.25	-0.55	-0.59	-0.14	-0.09	-0.45	-0.6	-0.25	-0.26	-0.35	-0.47	-0.17	-0.02	-0.28
Retained Earnings	-0.34	0.11	-0.26	0.26	0.29		-0.57	-0.41	-0.87	-0.91	-0.19	-0.91	-0.82	-0.42	-0.28	-0.78	-0.3	-0.73	-0.7	0.41	-0.55	0.14	-0.79	-0.8	-0.27	-0.05
Cash	0.65	0.06	0.63	0.31	-0.75	-0.57		0.68	0.73	0.63	-0.07	0.7	0.59	0.69	0.54	0.42	0.01	0.7	0.64	0.1	0.16	0.33	0.69	0.51	-0.05	0.26
Cash And Short Term Investments	0.96	-0.5	0.73	0.67	-0.56	-0.41	0.68		0.68	0.58	0.04	0.66	0.57	1.0	0.67	0.13	0.15	0.66	0.67	0.47	0.05	0.59	0.64	0.48	0.13	0.35
Common Stock Total Equity	0.65	-0.27	0.55	0.2	-0.45	-0.87	0.73	0.68		0.92	0.19	0.99	0.81	0.69	0.61	0.5	0.37	0.91	0.79	-0.05	0.27	0.27	0.91	0.74	0.33	0.18
Common Stock Shares Outstanding	0.46	-0.24	0.34	-0.04	-0.37	-0.91	0.63	0.58	0.92		0.17	0.94	0.83	0.59	0.42	0.6	0.29	0.7	0.76	-0.31	0.42	-0.05	0.73	0.8	0.26	0.17
Other Current Assets	0.04	-0.68	0.32	-0.02	0.0	-0.19	-0.07	0.04	0.19	0.17		0.21	0.15	0.04	0.31	-0.18	0.92	0.16	0.52	-0.05	-0.11	0.02	0.14	0.11	0.93	-0.07
Other Stockholder Equity	0.62	-0.28	0.49	0.14	-0.42	-0.91	0.7	0.66	0.99	0.94	0.21		0.82	0.67	0.59	0.54	0.39	0.88	0.79	-0.1	0.3	0.2	0.89	0.75	0.35	0.19
Total Liab	0.48	-0.24	0.31	-0.1	-0.25	-0.82	0.59	0.57	0.81	0.83	0.15	0.82		0.58	0.23	0.73	0.16	0.71	0.74	-0.27	0.41	0.0	0.73	0.99	0.11	0.14
Total Current Assets	0.96	-0.5	0.73	0.66	-0.55	-0.42	0.69	1.0	0.69	0.59	0.04	0.67	0.58		0.67	0.15	0.15	0.67	0.67	0.47	0.05	0.58	0.65	0.49	0.13	0.35
Common Stock	0.7	-0.44	0.65	0.7	-0.59	-0.28	0.54	0.67	0.61	0.42	0.31	0.59	0.23	0.67		-0.22	0.57	0.63	0.63	0.43	-0.35	0.62	0.54	0.12	0.48	0.29
Short Long Term Debt Total	0.04	0.25	-0.05	-0.58	-0.14	-0.78	0.42	0.13	0.5	0.6	-0.18	0.54	0.73	0.15	-0.22		-0.21	0.4	0.35	-0.59	0.7	-0.43	0.5	0.78	-0.25	-0.18
Property Plant And Equipment Net	0.18	-0.7	0.37	0.14	-0.09	-0.3	0.01	0.15	0.37	0.29	0.92	0.39	0.16	0.15	0.57	-0.21		0.35	0.56	0.03	-0.19	0.16	0.3	0.1	0.98	-0.04
Current Deferred Revenue	0.72	-0.24	0.67	0.33	-0.45	-0.73	0.7	0.66	0.91	0.7	0.16	0.88	0.71	0.67	0.63	0.4	0.35		0.74	0.23	0.21	0.54	0.99	0.6	0.33	0.16
Accounts Payable	0.63	-0.45	0.65	0.19	-0.6	-0.7	0.64	0.67	0.79	0.76	0.52	0.79	0.74	0.67	0.63	0.35	0.56	0.74		0.05	0.3	0.27	0.75	0.67	0.51	0.27
Non Current Assets Total	0.63	-0.28	0.59	0.88	-0.25	0.41	0.1	0.47	-0.05	-0.31	-0.05	-0.1	-0.27	0.47	0.43	-0.59	0.03	0.23	0.05		-0.34	0.93	0.17	-0.38	0.08	0.33
Non Currrent Assets Other	0.02	0.16	0.05	-0.49	-0.26	-0.55	0.16	0.05	0.27	0.42	-0.11	0.3	0.41	0.05	-0.35	0.7	-0.19	0.21	0.3	-0.34		-0.33	0.37	0.44	-0.13	-0.11
Other Assets	0.75	-0.28	0.71	0.88	-0.35	0.14	0.33	0.59	0.27	-0.05	0.02	0.2	0.0	0.58	0.62	-0.43	0.16	0.54	0.27	0.93	-0.33		0.46	-0.13	0.19	0.36
Good Will	0.69	-0.2	0.65	0.24	-0.47	-0.79	0.69	0.64	0.91	0.73	0.14	0.89	0.73	0.65	0.54	0.5	0.3	0.99	0.75	0.17	0.37	0.46		0.64	0.29	0.14
Non Current Liabilities Total	0.36	-0.18	0.16	-0.23	-0.17	-0.8	0.51	0.48	0.74	0.8	0.11	0.75	0.99	0.49	0.12	0.78	0.1	0.6	0.67	-0.38	0.44	-0.13	0.64		0.05	0.14
Property Plant And Equipment Gross	0.17	-0.71	0.39	0.15	-0.02	-0.27	-0.05	0.13	0.33	0.26	0.93	0.35	0.11	0.13	0.48	-0.25	0.98	0.33	0.51	0.08	-0.13	0.19	0.29	0.05		-0.03
Short Term Debt	0.36	0.1	0.01	0.33	-0.28	-0.05	0.26	0.35	0.18	0.17	-0.07	0.19	0.14	0.35	0.29	-0.18	-0.04	0.16	0.27	0.33	-0.11	0.36	0.14	0.14	-0.03

Click cells to compare fundamentals

Minerva Neurosciences Account Relationship Matchups

Minerva Neurosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	77.5M	57.6M	77.1M	55.1M	56.9M	88.0M
Other Current Liab	(41.2B)	2.1M	965.7K	407.9K	1.5M	1.6M
Total Current Liabilities	6.6M	3.2M	2.8M	1.4M	3.3M	4.4M
Total Stockholder Equity	27.8M	52.7M	8.0M	(20.0M)	(28.5M)	(27.0M)
Net Debt	(21.1M)	(25.2M)	(60.8M)	37.6M	(40.9M)	(38.9M)
Retained Earnings	(286.7M)	(284.8M)	(334.7M)	(366.8M)	(396.8M)	(377.0M)
Cash	21.4M	25.4M	60.8M	36.1M	40.9M	34.7M
Cash And Short Term Investments	45.9M	25.4M	60.8M	36.1M	41.0M	51.4M
Common Stock Total Equity	3.9K	3.9K	3.9K	4.3K	4.9K	3.0K
Common Stock Shares Outstanding	4.9M	5.1M	5.3M	5.3M	6.5M	4.6M
Liabilities And Stockholders Equity	77.5M	57.6M	77.1M	55.1M	56.9M	88.0M
Other Current Assets	1.3B	2.1M	1.4M	848.1K	1.1M	1.0M
Other Stockholder Equity	314.5M	337.5M	342.7M	346.8M	368.4M	264.5M
Total Liab	49.7M	5.0M	69.1M	75.1M	85.4M	42.7M
Total Current Assets	47.1M	27.4M	62.2M	40.2M	42.0M	52.9M
Common Stock	3.9K	4K	4.3K	534.0	699.0	664.05
Property Plant And Equipment Net	278K	101.8K	51.1K	16.3K	10.9K	10.3K
Accounts Payable	2.3M	995.6K	1.9M	969.7K	1.8M	1.5M
Non Current Assets Total	30.4M	30.2M	14.9M	14.9M	14.9M	27.9M
Non Current Liabilities Total	43.1M	1.8M	66.3M	73.7M	82.0M	41.8M
Property Plant And Equipment Gross	278.0K	101.8K	0.0	16.3K	18.8K	17.8K
Short Term Debt	4.0M	41.2B	173K	111.2K	127.9K	121.5K
Property Plant Equipment	33.5K	16.0K	101.8K	16.3K	18.8K	36.8K
Other Liab	43.0M	1.8M	66.3M	73.7M	84.8M	89.0M
Net Tangible Assets	(2.3M)	22.6M	(6.9M)	(34.9M)	(31.4M)	(29.9M)
Retained Earnings Total Equity	(164.4M)	(214.6M)	(286.7M)	(284.8M)	(256.3M)	(269.1M)
Short Term Investments	102.1M	37.8M	24.4M	100K	90K	85.5K
Capital Surpluse	296.0M	304.8M	314.5M	337.5M	388.1M	278.9M
Non Current Liabilities Other	41.2M	41.3M	66.3M	73.7M	82.0M	41.9M
Net Invested Capital	27.8M	52.7M	8.0M	(20.0M)	(28.5M)	(27.0M)
Net Working Capital	40.5M	24.3M	59.4M	38.8M	38.7M	46.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC